Objectives In most patients undergoing endoscopy for upper gastrointestinal (GI) symptoms in the Western world, no macroscopic abnormality or evidence of Helicobacter pylori infection is identified. Following this negative investigation, proton pump inhibitor (PPI) therapy is usually prescribed. The aim of this study was to assess the value of such treatment compared with placebo and to identify predictors of response.
Design Prospective parallel randomised study.
Setting Dyspepsia Research Clinic.
Participant 105 patients (49 men, median age 44 years, IQR 22) with normal endoscopy and H pylori negative with ongoing upper GI symptoms following 2-week run-in period.
Intervention Full demographic symptom severity and characteristics were assessed and 24 h oesophageal pH metry and oesophageal manometry were performed prior to randomisation to 2 weeks of treatment with lansoprazole 30 mg/day or placebo (2:1), with reassessment of symptom severity during the second week of treatment.
Primary outcome 50% reduction in Glasgow Dyspepsia Severity Score (GDSS).
Results According to intention to treat analysis, the response was 35.7% for the active group and 5.7% for the placebo group (p<0001). The only non-invasive independent predictor of response to PPI in multivariable analysis was the patient's body mass index (BMI) (p=0.003). The association of BMI with response to PPI was apparent across the full range of quartiles (p values for trend=0.01). BMI had a similar predictive value to either 24 h oesophageal pH metry or manometry. Predominant symptom and symptom subgroups were unhelpful in predicting the response to PPI. Including all pretreatment assessments, only BMI (p<0.05) and lower oesophageal sphincter pressure (p<0.05) were independent predictors of response.
Conclusion The response to PPI therapy is likely to be related to underlying acid reflux. The strong predictive value of BMI is probably due to its association with underlying reflux disease and the fact that it is a more objective and reproducible measure than symptom characteristics. It is recommended that BMI should be measured in patients with upper GI symptoms.
Trial Registration Number ISRCTN 32863375.
- upper gastrointestinal
- non-erosive reflux disease
- proton pump inhibitor
- non-ulcer dyspepsia
- proton pump inhibition
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Funding This study received partial financial support from Wyeth Pharmaceuticals.
Competing interests None.
Patient consent Obtained.
Ethics approval This study was conducted with the approval of the Greater Glasgow Health Board – The West Ethical Committee.
Provenance and peer review Not commissioned; externally peer reviewed.